Home > News > Mednax Can Sustain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
October 25th, 2010
Mednax Can Sustain EPS Growth By Consolidating Nanotechnology, Morgan Keegan Reports
Abstract:
Morgan Keegan said that its EPS estimate of $1.05 versus $1.03 in the prior year period is in line with the First Call consensus, adding, "We are confident that the company's earnings will at least meet Mednax's guidance of $1.03-$1.07."
Mednax closed Friday at $56.96.
Source:
benzinga.com
Related News Press |
News and information
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||